Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer

A. Jänne, Pasi; Baik, Christina; Su, Wu-Chou; L. Johnson, Melissa; Hayashi, Hidetoshi; Nishio, Makoto; Kim, Dong-Wan; Koczywas, Marianna; A. Gold, Kathryn; E. Steuer, Conor; Murakami, Haruyasu; Chih-Hsin Yang, James; Kim, Sang-We; Vigliotti, Michele; Shi, Rong; Qi, Zhenhao; Qiu, Yang; Zhao, Lihui; Sternberg, David; Yu, Channing; A. Yu, Helena

doi:10.1158/2159-8290.cd-21-0715

Public

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer

Published in Cancer Discovery • Sep 21, 2021

Authors:

Pasi A. Jänne

Christina Baik

Wu-Chou Su

Abstract

Abstract Receptor tyrosine-protein kinase ERBB3 (HER3) is expressed in most EGFR-mutated lung cancers but is not a known mechanism of resistance to EGFR inhibitors. HER3-DXd is an antibody–drug conjugate consisting of a HER3 antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide...

View

Open Access

Subject

Medicine

Lung cancer

Internal medicine

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!